Amylyx Pharmaceuticals, Inc. Operating Lease Liability
Amylyx Pharmaceuticals, Inc. (AMLX) had Operating Lease Liability of $5.96 million as of 2025-12-31, per its 10-K filed 2026-03-03.
Financial Statements › Balance Sheet › Liabilities
us-gaap:OperatingLeaseLiability · last filed 2026-03-03
- 2025-12-31: Operating Lease, Liability $5.96M.
- 2024-12-31: Operating Lease, Liability $1.98M.
- 2024-09-30: Operating Lease, Liability $5.10M.
- 2024-09-12: Operating Lease, Liability $5.10M.
| Period end | Operating Lease, Liability |
|---|---|
| 2025-12-31 | $5.96M 10-K · filed 2026-03-03 |
| 2024-12-31 | $1.98M 10-K · filed 2026-03-03 |
| 2024-09-30 | $5.10M 10-Q · filed 2025-11-06 |
| 2024-09-12 | $5.10M 10-K · filed 2026-03-03 |
| 2023-12-31 | $4.24M 10-K · filed 2025-03-04 |
| 2023-09-30 | $4.77M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $5.29M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $5.79M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $6.28M 10-K · filed 2024-02-22 |
| 2022-09-30 | $6.76M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $7.07M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $7.19M 10-Q · filed 2022-05-12 |
| 2022-01-10 | $5.00M 10-K · filed 2024-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |